scholarly journals Age-related changes in human oestrogen receptor α function and levels in osteoblasts

1998 ◽  
Vol 333 (3) ◽  
pp. 787-794 ◽  
Author(s):  
Michael A. ANKROM ◽  
Julie A. PATTERSON ◽  
Patricia Y. d'AVIS ◽  
Ulrich K. VETTER ◽  
Marc R. BLACKMAN ◽  
...  

Oestrogen receptors (ERs) are present in human osteoblasts and mediate anti-resorptive effects on bone. Human osteoblast-like cells derived from different aged healthy female donors not on hormone replacement therapy were utilized under well-defined conditions in vitro to investigate ER function and levels. Treatment with 0.1 nM oestradiol-17β of cell strains derived from eight young women (less than 50 years of age) increased hydroxyproline levels significantly [an average (2.2±0.1 S.E.M.)-fold increase], whereas cells derived from nine older women (more than 50 years of age) were not significantly affected. Similarly, cell strains, derived from younger women, transfected with a consensus oestrogen-responsive element linked to chloramphenicol acetyltransferase exhibited a greater response to oestrogen than strains derived from older women. When basal ERα levels were measured by enzyme immunoassay and normalized on a per cell basis, osteoblast-like strains derived from younger women (n = 24) had a mean value of 2.54±0.16 fmol of ERα per 106 cells. In contrast, strains derived from older women (n = 20) had a mean value of 5.44±0.48 fmol of ERα per 106 cells. An age-related increase in ERα number was also observed in human skin-derived fibroblasts and directly in dermal biopsies from women not on hormone replacement therapy. The results demonstrate ligand concentration-dependent ERα induction and indicate a loss of receptor regulation and diminution of ligand–receptor signal transduction with increasing donor age.

Neurology ◽  
2001 ◽  
Vol 57 (12) ◽  
pp. 2210-2216 ◽  
Author(s):  
M. C. Carlson ◽  
P. P. Zandi ◽  
B. L. Plassman ◽  
J. T. Tschanz ◽  
K. A. Welsh-Bohmer ◽  
...  

2001 ◽  
Vol 10 (4) ◽  
pp. 343-350 ◽  
Author(s):  
Meredith M. Regan ◽  
Sarah K. Emond ◽  
Mary J. Attardo ◽  
Robert A. Parker ◽  
Susan L. Greenspan

2005 ◽  
Vol 17 (2) ◽  
pp. 155-164 ◽  
Author(s):  
Osvaldo P. Almeida ◽  
Leon Flicker

The results of in vitro and animal studies provide a strong rationale for the use of hormone replacement therapy (HRT) to prevent dementia and Alzheimer's disease (AD). In humans, the results of 16 observational studies are consistent with the hypothesis that estrogen use reduces the risk of AD by 10 to 60%. However, women who are prescribed HRT are less likely to have hypertension, diabetes and history of stroke than nonusers. As all of these factors have been associated with increased risk of dementia (including AD), this “prescription bias” may have a significant impact on the results of observational studies. Randomized trials are designed with the aim of avoiding many of the potential biases and confounding (measured or unmeasured) of observational studies. The results of the Women's Health Initiative Memory Study (WHIMS) indicate that HRT (estrogen plus progestin or estrogen alone) increases the risk of dementia (hazard ratio, HR=1.8, 95% CI=1.2–2.6). Taking into account the results of the WHIMS and the adverse health events associated with the use of estrogen plus progestin or estrogen alone, we conclude that HRT cannot be recommended as a safe and effective strategy to prevent dementia.


2004 ◽  
Vol 19 (7) ◽  
pp. 791-804 ◽  
Author(s):  
Shelley R. Salpeter ◽  
Judith M. E. Walsh ◽  
Elizabeth Greyber ◽  
Thomas M. Ormiston ◽  
Edwin E. Salpeter

Maturitas ◽  
2006 ◽  
Vol 55 (4) ◽  
pp. 325-333 ◽  
Author(s):  
Fréderique Retornaz ◽  
Françoise Paris ◽  
Serge Lumbroso ◽  
Françoise Audran ◽  
Fabien Tigoulet ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document